Mesoblast Withdraws $50 Mln From Five-Year Non-Dilutive Facility

June 25, 2026 — 06:56 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Mesoblast Limited (MESO), a commercial-stage biotechnology company, announced that it has drawn $50 million from a five-year facility provided by Gregory George, a director and shareholder of the company.

The company intends to use the credit facility to support its commercial operations and pipeline growth, while optimizing its capital structure through repayment of debt liability owed to NovaQuest Capital Management LLC and other short-term debt obligations.

Under the terms of the agreement, the company is required to carry out repayment of the facility using Temcell1 royalties, at a fixed interest rate of 8.00% per annum with a five-year interest only period.

As of March 30, 2026, the company reported cash holdings totalling $122 million.

Mesoblast has traded between $10.32 and $21.50 over the last year.

MESO closed Wednesday at $15.55, up 1.11%.

For more such biotechstock news visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Mesoblast Withdraws $50 Mln From Five-Year Non-Dilutive Facility

Tags

Latest Articles